Ionis Pharmaceuticals Inc
IONS76.090USD
+2.970+4.06%
收盤 11/21, 16:00（美東）報價延遲15分鐘
12.26B總市值
虧損本益比TTM
關於 Ionis Pharmaceuticals Inc 公司
Ionis Pharmaceuticals, Inc. 從事核糖核酸 (RNA) 靶向治療。該公司有五種已上市藥物和一條產品線，涉及神經病學、心臟病學和其他患者需求高的領域。該公司有九種藥物處於 III 期開發階段，還有多種其他藥物處於早期和中期開發階段。該公司的產品包括 SPINRAZA、QALSODY、WAINUA、TEGSEDI 和 WAYLIVRA。SPINRAZA 用於治療脊髓性肌萎縮症 (SMA) 患者，這是一種進行性、使人衰弱且通常致命的遺傳疾病。QALSODY 是一種反義藥物，用於治療超氧化物歧化酶 1 肌萎縮側索硬化症 (SOD1-ALS) 的成年患者，這是一種罕見的神經退行性疾病，會導致運動神經元逐漸喪失並導致死亡。 WAINUA 是一種自行注射的皮下配體結合反義 (LICA) 藥物，用於治療患有遺傳性轉甲狀腺素介導的澱粉樣變性多發性神經病 (ATTRv-PN) 的成年人。
Ionis Pharmaceuticals Inc簡介
公司代碼IONS
公司名稱Ionis Pharmaceuticals Inc
上市日期May 17, 1991
CEODr. Brett P. Monia, Ph.D.
員工數量1069
證券類型Ordinary Share
年結日May 17
公司地址2855 Gazelle Court
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92010
電話17609319200
網址https://www.ionis.com/
公司代碼IONS
上市日期May 17, 1991
CEODr. Brett P. Monia, Ph.D.
Ionis Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
-18.30%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
+9.77%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
收入明細
單位: USD更新時間: 3月4日 週二
單位: USD更新時間: 3月4日 週二
FY2020
FY2019
業務USD
名稱
營收
佔比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
股東統計
更新時間: 11月19日 週三
更新時間: 11月19日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
其他
54.02%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
其他
54.02%
股東類型
持股股東
佔比
Investment Advisor
68.55%
Investment Advisor/Hedge Fund
19.48%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
State Street Investment Management (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco Biotechnology & Genome ETF
4.15%
ARK Genomic Revolution ETF
3.61%
Virtus LifeSci Biotech Products ETF
3.06%
Invesco Dorsey Wright Healthcare Momentum ETF
2.45%
SPDR S&P Biotech ETF
2.11%
VanEck Morningstar SMID Moat ETF
1.89%
Tema Heart & Health ETF
1.62%
Capital Group US Small and Mid Cap ETF
1.34%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
iShares Biotechnology ETF
0.98%
查看更多
Invesco Biotechnology & Genome ETF
佔比4.15%
ARK Genomic Revolution ETF
佔比3.61%
Virtus LifeSci Biotech Products ETF
佔比3.06%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比2.45%
SPDR S&P Biotech ETF
佔比2.11%
VanEck Morningstar SMID Moat ETF
佔比1.89%
Tema Heart & Health ETF
佔比1.62%
Capital Group US Small and Mid Cap ETF
佔比1.34%
Direxion Daily S&P Biotech Bull 3X Shares
佔比1.11%
iShares Biotechnology ETF
佔比0.98%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Ionis Pharmaceuticals Inc的前五大股東是誰？
Ionis Pharmaceuticals Inc的前五大股東如下：
Fidelity Management & Research Company LLC持有股份：23.64M佔總股份比例：14.83%。
The Vanguard Group, Inc.持有股份：16.68M佔總股份比例：10.47%。
T. Rowe Price Investment Management, Inc.持有股份：16.05M佔總股份比例：10.07%。
Capital World Investors持有股份：12.54M佔總股份比例：7.87%。
BlackRock Institutional Trust Company, N.A.持有股份：8.73M佔總股份比例：5.47%。
Fidelity Management & Research Company LLC持有股份：23.64M佔總股份比例：14.83%。
The Vanguard Group, Inc.持有股份：16.68M佔總股份比例：10.47%。
T. Rowe Price Investment Management, Inc.持有股份：16.05M佔總股份比例：10.07%。
Capital World Investors持有股份：12.54M佔總股份比例：7.87%。
BlackRock Institutional Trust Company, N.A.持有股份：8.73M佔總股份比例：5.47%。
Ionis Pharmaceuticals Inc的前三大股東類型是什麼？
Ionis Pharmaceuticals Inc 的前三大股東類型分別是：
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
有多少機構持有Ionis Pharmaceuticals Inc(IONS)的股份？
截至2025Q3，共有815家機構持有Ionis Pharmaceuticals Inc的股份，合計持有的股份價值約為172.95M，占公司總股份的106.78% 。與2025Q2相比，機構持股有所增加，增幅為-9.56%。
哪個業務部門對Ionis Pharmaceuticals Inc的收入貢獻最大？
在FY2020，R&D revenue under collaborative agreements業務部門對Ionis Pharmaceuticals Inc的收入貢獻最大，創收364.56M，占總收入的49.99% 。
